Sixth / CRT / Research UK / Chroma / Therapeutics Ltd / European Investment Fund / Element Capital LLP / Research Technology / PIONEER FUND / Cancer / Wellcome Trust / /
Continent
Europe / /
Country
United Kingdom / /
Currency
GBP / EUR / /
Event
Business Partnership / Funding / /
Facility
Queen Mary University of London / Barts Cancer Institute / /
IndustryTerm
biotechnology / owned subsidiary / chemical motifs / cancer therapeutics / intracellular accumulation technologies / media enquiries / finance / value chain / treatment of cancer / healthcare markets / /
MedicalCondition
potential cancer / lymphoma and pancreatic tumours / cancer / inflammatory disorders / tumour / international cancer / potential new cancer / tumours / /
MedicalTreatment
cancer therapeutics / /
Organization
Financial Services Authority / European Union / University of London / /
Person
Bungay / James / Blundy / / /
Position
Queen / chief executive / chief executive of Cancer Research Technology / managing partner / /
Technology
biotechnology / CANCER RESEARCH TECHNOLOGY / ESM technology / drug discovery / intracellular accumulation technologies / Research Technology / /
Strict
Embargo:
00:01hrs
UK
Thursday
31
October,
2013
CRT
PIONEER
FUND
COLLABORATES
WITH
CHROMA
THERAPEUTICS
TO
DEVELOP
CANCER
DRUGS
TA